{
    "title": "UPDATE 2-Synairgen soars after drug shows promise in COVID-19 cases",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-8540291/Synairgen-shares-soar-drug-shows-lower-risk-severe-COVID-19-cases.html",
    "date": "2020-07-20",
    "keywords": [
        "covid19",
        "treatment",
        "study",
        "medicine",
        "risk",
        "market",
        "sng001",
        "drug",
        "synairgen",
        "aakash",
        "b",
        "july",
        "monday",
        "drugmaker",
        "optimism",
        "companys",
        "formulation",
        "interferon",
        "beta",
        "disease",
        "coronavirus",
        "death",
        "placebo",
        "trial",
        "assessment",
        "breakthrough",
        "executive",
        "richard",
        "marsden",
        "record",
        "high",
        "pence",
        "afternoon",
        "cap",
        "friday",
        "form",
        "protein",
        "everyone",
        "professor",
        "pharmacoepidemiology",
        "school",
        "hygiene",
        "britain",
        "age",
        "duration",
        "enrolment",
        "need",
        "measure",
        "breathlessness",
        "university",
        "southampton",
        "lung",
        "medication",
        "jagadeesh",
        "babu",
        "pushkala",
        "aripaka",
        "bengaluru",
        "editing",
        "bernard",
        "orr",
        "edmund",
        "blair"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}